The European Union's current pressure on Member States to adopt the Green Deal and the Fit for 55 package is leading to an accelerated drive to put in place measures to meet the 2030 climate targets. At the same time, many discussions at international bilateral meetings of EU country representatives raise the question of the realism of setting climate targets and therefore the ability to meet these commitments. The results elaborated in this analytical study offer a realistic picture of the possibilities of meeting strategic climate targets using the example of the use of forest dendromass for the ability to achieve a 22% share of renewable energy sources (RES) in gross final energy consumption by 2030 in the Czech Republic. The study points out that at present the use of forest dendromass from primary pro-duction is at its maximum and meeting the climate targets for increasing the share of RES in the energy mix represents a major problem in the long term. The findings published in this study also point to the objective threat of increased use of dendrmass in the energy sector to the maintenance of sustainable forest management and the preservation of forest quality.

Lipid-lowering therapy (LLT) is a cornerstone of atherosclerotic cardiovascular disease prevention. Although LLT might lead to different reductions in low-density lipoprotein cholesterol (LDL-C) levels in women and men, LLT diminishes cardiovascular risk equally effectively in both sexes. Despite similar LLT efficacy, the use of high-intensity statin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors is lower in women compared to men. Women achieve the guideline-recommended LDL-C levels less often than men. Greater cholesterol burden is particularly prominent in women with familial hypercholesterolemia. In clinical practice, women and men with dyslipidemia present with different cardiovascular risk profiles and disease manifestations. The concentrations of LDL-C, lipoprotein(a) and other blood lipids differ between women and men over a lifetime. Dissimilar levels of LLT’s target molecules partially result from sex-specific hormonal and genetic determinants of lipoprotein metabolism. Hence, to evaluate a potential need for sex-specific LLT, this comprehensive review (i) describes the impact of sex on lipoprotein metabolism and lipid profile, (ii) highlights sex differences in cardiovascular risk among patients with dyslipidemia, (iii) presents recent, up-to-date clinical trial and real-world data on LLT efficacy and safety in women, and (iv) discusses diverse medical needs of women and men with dyslipidemia and increased cardiovascular risk.